Daily Medication Pearl: Buprenorphine (Butrans)

Buprenorphine (Butrans) is a partial opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.

Medication Pearl of the Day: Buprenorphine (Butrans)

Indication: Buprenorphine (Butrans) is a partial opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.

Insight:

  • Dosing: Doses of 7.5, 10, 15, and 20 mcg/hour are for opioid experienced patients only.
  • Dosage forms: Transdermal system 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour, and 20 mcg/hour.
  • Adverse events: Most common adverse reactions (≥ 5%) include nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, and application site rash.
  • Mechanism of action: Buprenorphine is a partial agonist at mu opioid receptors.

Source: BUTRANS label (fda.gov)

Related Content:

HospitalRetailPain Management
FDA Accepts Aflibercept sBLA for Treatment of Diabetic Retinopathy
Treatment with Ofatumumab Increases Number of Patients Who Achieve No Evidence of Disease Activity for MS
Bringing Oncology Pharmacy Leaders, Payers Together to Address Unmet Educational Needs in the Field